Fig. 1: Design of regorafenib@mannose-γ-cyclodextrin channel-type nanoparticles (abbreviated as RG@M-γ-CD CNPs) and the synergetic anti-CRC mechanism. | Nature Communications

Fig. 1: Design of regorafenib@mannose-γ-cyclodextrin channel-type nanoparticles (abbreviated as RG@M-γ-CD CNPs) and the synergetic anti-CRC mechanism.

From: Cyclodextrin-based host-guest complexes loaded with regorafenib for colorectal cancer treatment

Fig. 1

RG@M-γ-CD CNPs inhibit tumor cell survival, lesion angiogenesis, attenuate inflammation and suppress tumor-associated macrophages activation through potentiating the kinase suppression of regorafenib and exerting the biological function of cyclodextrin.

Back to article page